Abstract-Ubiquitin-specific protease 18 (USP18), a USP family member, is involved in antiviral activity and cancer inhibition. Although USP18 is expressed in heart, the role of USP18 in the heart and in cardiac diseases remains unknown. Here, we show that USP18 expression is elevated in both human dilated hearts and hypertrophic murine models. Cardiomyocyte-specific overexpression of USP18 in mice significantly blunted cardiac remodeling as evidenced by mitigated myocardial hypertrophy, fibrosis, ventricular dilation, and preserved ejection function, whereas USP18-deficient mice displayed exacerbated cardiac remodeling under the same pathological stimuli. Similar results were observed for in vitro angiotensin II-induced neonatal rat cardiomyocyte hypertrophy. The antihypertrophic effects of USP18 under hypertrophic stimuli were associated with the blockage of the transforming growth factor-β-activated kinase 1-p38/c-Jun N-terminal kinase 1/2 signaling cascade. Blocking transforming growth factor-β-activated kinase 1-p38/c-Jun N-terminal kinase 1/2 signaling with a pharmacological inhibitor (5Z-7-oxozeaenol) greatly reversed the detrimental effects observed in USP18-knockout mice subjected to aortic banding. Our data indicate that USP18 inhibits cardiac hypertrophy and postpones cardiac dysfunction during the remodeling process, which is dependent on its modulation of the transforming growth factor-β-activated kinase 1-p38/c-Jun N-terminal kinase 1/2 signaling axis. Thus, USP18 is a potent therapeutic target for heart failure treatment.
C ardiovascular diseases such as hypertension and aortic stenosis impose a hemodynamic overload on ventricular walls, activating complicated signaling transduction pathways and biological responses, leading to cardiac remodeling. 1, 2 Cardiac remodeling starts as compensatory left ventricular hypertrophy but eventually evolves into maladaptive remodeling, triggering the transition to heart failure. 3 Numerous intracellular signaling pathways are involved in this pathological process, resulting in fetal gene re-expression, cardiac myocyte enlargement, and fibrosis, which all facilitate the development of end-stage heart failure. 1, 4 Elucidating the mechanisms underlying this pathological process and discovering more selective targets is a future endeavor in the treatment of heart failure.
Ubiquitin-specific protease 18 (USP18) is a USP family member. 5 As an interferon-stimulated gene, USP18 inhibits type I interferon signaling, thus forming a negative feedback loop. 6 USP18 also functions as an isopeptidase responsible for cleaving the ubiquitin-like protein ISG15 and removing polyubiquitin chains from specific substrates. 7, 8 USP18 is highly expressed in hematopoietic organs such as the thymus and the fetal spleen. 5, 9 The thorough dissection of USP18 unraveled its role in antiviral activity and cancer inhibition. [10] [11] [12] Intriguingly, the gene encoding human USP18 is located on chromosome 22q11.2 in a minimal region deleted in DiGeorge syndrome, which is characterized by immune deficiencies and congenital cardiac abnormalities. 9 Emerging evidence has shed light on the relevance of USP18 to several well-known signaling pathways that participate in cardiac remodeling, including nuclear factor κB, calcineurin-nuclear factor of activated T cells, transforming growth factor-β-activated kinase 1 (TAK1) signaling. 8, 13 The functional impact on these pivotal signaling pathways in the heart suggest that USP18 may play a novel role in cardiac pathophysiology. Although USP18 expression is evident in the heart, 9 its function remains unexplored. Thus, a detailed analysis of the consequences of USP18 ablation and overexpression in hearts and the mechanisms by which USP18 is involved in this remodeling process will provide insight.
USP18-deficient mice were first generated on a C57BL/6 and 129S mixed background. These mice displayed neurological disorders and died within 20 weeks. 14 Whereas, USP18 null mice on a pure C57BL/6 background were embryonically lethal. 15 USP18-knockout (KO) mice on an FVB (Friend Virus B) background spontaneously developed tumors between 6 and 12 months. 16 In this study, we generated USP18-KO mice on a CD1 background; these mice were viable and did not exhibit apparent abnormalities at baseline. The USP18-KO CD1 mice together with the USP18 cardiac-specific transgenic (TG) mice on a C57BL/6 background were then used to determine the role of USP18 in pathological cardiac remodeling. USP18 overexpression mitigated cardiac hypertrophy, alleviated pathological fibrosis, and eventually postponed cardiac dysfunction. Furthermore, our results indicate that USP18 functions as an inhibitor of pathological cardiac remodeling by modulating TAK1-dependent p38 and c-Jun N-terminal kinase 1/2 (JNK1/2) signaling.
Materials and Methods
Detailed methods are available in the online-only Data Supplement.
Generation of Cardiac-Specific USP18-Transgenic (USP18-TG) Mice
To generate USP18-TG mice, cDNA containing full-length mouse USP18 was cloned, and the transgene vector pCAG-loxP-CATloxP-USP18 was constructed by replacing the lacZ gene in pCAGloxP-CAT-loxP-lacZ with the cDNA of full-length mouse USP18. CAG-CAT-USP18 TG mice was produced by microinjecting this construct into fertilized C57BL/6J mouse embryos. 17 To induce USP18 expression specifically in the heart, CAG-CAT-USP18 TG mice were bred with mice that carried the Cre gene under the control of the cardiac-specific α-myosin heavy chain (α-MHC) promoter. Cardiac-specific expression of the USP18 was induced in CAG-CAT-USP18/α-MHC-Cre TG mice by tamoxifen treatment, which allowed Cre-mediated CAT gene excision. Tail genomic DNA was amplified by polymerase chain reaction with the following primers: forward: 5′-CCCCCTGAACCTGAAACATA-3′; reverse: 5′-TCCGAGGCACTGTTATCCTC-3′. The expected size for the amplification product was 601 bp. Western blot analysis was used to confirm the protein expression of USP18 ( Figure S1 ).
Statistical Analysis
All of the data are expressed as the mean±SD. 18 We used SPSS 19.0 software to perform the statistical analysis in this study. Student unpaired t tests (between 2 groups) and 1-way ANOVA (for >2 groups) followed by Bonferroni (equal variances assumed) or Tamhane T2 (equal variances not assumed) were used where applicable. P<0.05 was considered statistically significant.
Results

USP18 Is Functionally Expressed in Human and Murine Hearts
We first investigated the cellular localization of USP18, which showed mainly cytoplasm distribution ( Figure S6 ). We then evaluated whether the expression of USP18 is altered under pathological stimuli. Western blot analysis showed significant increase in the expression of hypertrophic markers (atrial natriuretic factor and β-MHC) in hearts of patients with dilated cardiomyopathy ( Figure 1A ). Moreover, we observed markedly increased USP18 protein levels in dilated cardiomyopathy hearts compared with normal donor hearts Figure 1A ). Next, we analyzed USP18 expression in pressure overload-induced hypertrophic murine models. The cardiac USP18 expression in the aortic banding (AB)-treated mice was ≈2-fold higher after AB surgery and remained higher even at 8 weeks compared with sham-operated mice ( Figure 1B) . Consistently, USP18 expression was tripled in neonatal rat cardiomyocytes (NRCMs) after stimulation with angiotensin II for 48 hours ( Figure 1C) . Collectively, we can conclude that cardiac USP18 expression is elevated during the hypertrophic process, and this alteration may imply functional relevance.
USP18 Inhibits Cardiomyocyte Hypertrophy In Vitro
To test the assumption that USP18 may participate in cardiac hypertrophy, NRCMs were infected with AdshUSP18 to silence USP18 expression or with AdUSP18 to induce USP18 overexpression (Figure 2A ), followed by angiotensin II stimulation. NRCMs were assayed by immunofluorescence studies, 19 and we observed that the overexpression of USP18 inhibited cardiomyocyte hypertrophy, whereas silencing USP18 exaggerated the hypertrophic response ( Figure 2B through 2F) . Meanwhile, USP18 overexpression inhibited atrial natriuretic factor and β-MHC expression, whereas USP18 deficiency augmented it ( Figure 2E and 2F). Thus, the in vitro data suggest that USP18 exerted a protective role in the heart with respect to cardiac hypertrophy.
USP18 Ablation Deteriorates Cardiac Remodeling
To further confirm the regulatory effect of USP18 in vivo, we generated systemic USP18 gene KO (USP18-KO) mice (Figure S3). Pressure overload by AB caused a marked increase in the heart weight (HW)/body weight ratio, the HW/tibia length ratio, and the HW/lung weight ratio in wild-type (WT) mice, whereas these alterations were augmented in USP18-KO mice subjected to AB ( Figure 3A) . Functionally, echocardiographic measurements showed enlarged left ventricular end-diastolic and end-systolic dimensions and reduced ejection fraction in USP18-KO mice compared with WT mice after AB surgery ( Figure 3B ). Morphologically, the cardiomyocytes crosssectional area was much larger in the USP18-KO mice compared with the AB-operated WT mice ( Figure 3C and 3D ). In addition, the mRNA levels of hypertrophic markers including atrial natriuretic factor, brain natriuretic peptide, and β-MHC were significantly increased in the AB-operated USP18-KO mice compared with the WT mice ( Figure 3F) .
Analysis of the picrosirius red-stained heart sections showed marked perivascular and interstitial fibrosis in the USP18-KO AB-operated mice compared with the WT mice ( Figure 3C and 3E) . The subsequent assessment of collagen volume and fibrotic markers (collagen I, collagen III, and connective tissue growth factor) demonstrated that USP18 ablation worsened the pathological fibrosis in response to AB surgery ( Figure 3F ). Altogether, these results indicated that USP18 deficiency exaggerated pressure overload-induced remodeling in AB-treated mice.
USP18 Overexpression Alleviates Cardiac Remodeling
We next investigated whether the cardiac-specific overexpression of USP18 (USP18-TG) attenuated cardiac remodeling. B, Echocardiographic parameters in the indicated groups after AB surgery (n=6-7/ group). C, Hematoxylin and eosin (H&E) staining, fluorescein isothiocyanateconjugated wheat germ agglutinin (WGA) staining, and picrosirius red-staining heart slices from the indicated groups (n=6-7/ group, scale bars are as indicated). D, Cross-sectional area of cardiomyocytes in the indicated groups (n=5/group, 100 cells were calculated). E, Collagen volume of fibrotic areas in the indicated groups (n≥25 fields/group). F, Real-time polymerase chain reaction analyses of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), β-myosin heavy chain (β-MHC), collagen I, collagen III, and connective tissue growth factor (CTGF) in the indicated groups (n=4/group). *P<0.05 vs nontransgenic (NTG)/sham; #P<0.05 vs NTG/AB. The data are expressed as mean±SD. EF indicates ejection fraction; LVESd, LV end-systolic dimension; and LVEDd, LV end-diastolic dimension.
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We generated and established 4 lines of USP18-TG mice and verified the protein expression of USP18 in these TG lines with Western blot assay ( Figure S1 ). TG line 4, with the highest USP18 protein expression, was chosen for subsequent studies. As shown in Figure 4A , USP18-TG mice showed a blunted hypertrophic response under AB surgery, which was indicated by the decreased HW/body weight, lung weight/body weight, and HW/tibia length ratios in the USP18-TG mice compared with the nontransgenic (NTG) mice. Functionally, the echocardiography measurement showed postponed cardiac dilation and dysfunction in USP18-TG mice subjected to AB compared with NTG mice (Figure 4B ). In addition, the cardiomyocyte cross-sectional area of the USP18-TG mice was much smaller than that of the NTG mice after AB ( Figure  4C and 4D) , accompanied by reduced mRNA expression of hypertrophic markers (atrial natriuretic factor, brain natriuretic peptide, and β-MHC) in the TG group compared with the NTG mice ( Figure 4F) .
Furthermore, the USP18-TG mice exhibited alleviated pathological fibrosis as demonstrated by reduced perivascular and interstitial collagen deposition, reduced collagen volume, and decreased mRNA expression of fibrotic indicators compared with the NTG AB-operated mice ( Figure 4C , 4E, and 4F). Therefore, the cardiac-specific overexpression of USP18 protects against cardiac remodeling induced by pressure overload.
USP18 Regulates TAK1-p38/JNK1/2 Signaling via Deubiquitination of TAK1
The cardiac mitogen-activated protein kinase (MAPK) signaling pathways can be activated by various stimuli to facilitate maladaptive remodeling. 20 At 4 weeks after AB, the levels of phosphorylated p38 and JNK1/2 were greatly increased in the WT hearts. In addition, the degree of p38 and JNK1/2 activation was markedly augmented in the USP18-KO hearts than in the WT hearts ( Figure 5A) . Conversely, the AB-induced activation of p38 and JNK1/2 was primarily inhibited in the USP18-TG mice ( Figure 5B), which was consistent to our in vitro study ( Figure 5C and 5D) .
The activation of TAK1 is an upstream event of p38 and JNK1/2 phosphorylation. 21, 22 We, therefore, investigated whether TAK1 activation is regulated by USP18 in current model. Our experiments clearly revealed that the expression level of phosphorylated TAK1 was significantly higher in the USP18-KO mice than in the WT mice subjected to AB surgery ( Figure 5A ). By contrast, the elevated expression levels of phosphorylated TAK1 after AB were significantly reduced in USP18 TG hearts compared with NTG mice (Figure 5B ), which was further confirmed by the in vitro experiment ( Figure 5C and 5D) . The above results indicated that the antihypertrophic effect of USP18 is associated with the inhibition of TAK1-p38/JNK1/2 activation.
To further investigate the mechanism underlying the effect of USP18 on TAK1 signaling, we first performed co-immunoprecipitation assay to determine whether endogenous USP18 physically interacted with TAK1. As shown in Figure 5E , we observed apparent binding of USP18 with TAK1 and vice versa. Considering that USP18 is a deubiquitinating enzyme, 5 and ubiquitination of TAK1 is essential for its activation, 23 we tested whether USP18 regulated TAK1 ubiquitination in hypertrophied cardiomyocytes. After angiotensin II stimulation for 24 hours, ubiquitination of TAK1 showed more robust augmentation in NRCMs transfected with AdshUSP18 compared with AdshRNA groups. Consistently, NRCMs transfected with AdUSP18 showed the diminished level of ubiquitinated TAK1 in Western blot assay compared with AdGFP group (Figure 5F ), suggesting USP18 deubiquitinated TAK1 in hypertrophied cardiomyocytes. Taken together, USP18 may regulate TAK1-p38/JNK1/2 signaling via direct binding with and deubiquitination of TAK1 in current model.
TAK1 Blockage Ameliorates Cardiac Remodeling in USP18-KO Mice
These results indicated that the inhibitory effect of USP18 in cardiac hypertrophy was likely depending on the regulation of TAK1 signaling. To confirm these findings, we evaluated whether the abnormalities in USP18-KO mice could be reversed by blocking TAK1 signaling with a pharmacological TAK1 inhibitor (5Z-7-ox) in vivo after AB surgery. Western blot analysis showed that 5Z-7-ox treatment significantly reduced the expression levels of phosphorylated TAK1, p38, and JNK1/2 in hearts compared with dimethyl sulphoxidetreated controls 4 weeks after AB ( Figure 6A ). Remarkably, 5Z-7-ox treatment rescued the detrimental phenotype of USP18-KO mice in response to pressure overload as shown by the following observations: (1) reduced HW/lung weight, HW/tibia length, and lung weight/body weight ratios ( Figure  6B ); (2) smaller heart and myocyte size ( Figure 6C) ; (3) decreased cross-sectional myocyte area ( Figure 6D) ; and (4) improved myocardial function ( Figure 6F ) in 5Z-7-ox-treated USP18-KO mice compared with dimethyl sulphoxide-treated USP18-KO mice on AB surgery. In addition, AB-induced cardiac fibrosis was significantly limited in 5Z-7-ox-treated USP18-KO mice compared with dimethyl sulphoxide-treated USP18-KO mice ( Figure 6C and 6E) . Thus, the above findings demonstrate that TAK1 inhibition could offset the negative effect of USP18 ablation in response to pressure overload. Taken together, the cardiac protective role of USP18 is likely attributed to the blockage of TAK1 signaling.
Discussion
We identified USP18 as an essential component of cardiac remodeling in response to pressure overload. Its overexpression protected hearts against maladaptive hypertrophy, fibrosis, and dilatation, which might contribute to the preserved systolic function because left ventricle dilation and cardiac fibrosis lead to distorted and ineffective contractile performance. 24 By contrast, its ablation hastened the transition toward decompensated heart failure. Mechanistically, we demonstrated that the antihypertrophic effect of USP18 was attributed to the repression of TAK1, thereby suppressing downstream p38 and JNK1/2 signaling, as the decrease in TAK1 activity induced by a TAK1 inhibitor (5Z-7-ox) rescued the exaggerated response of pathological cardiac remodeling in USP18-KO mice. Thus, for the first time, our work defines the functional role of USP18 in the heart and indicates that USP18 is a promising therapeutic target in treating pathological cardiac remodeling. In this study, the upregulation of USP18 expression was observed in both failing human hearts and hypertrophic murine hearts. There are several hypotheses for this increased USP18 protein expression. First, a compensatory response may occur in pathological remodeling. Similar to other negative cardiac regulators, 25, 26 USP18 may increase to play a Figure 6 . Transforming growth factor-β-activated kinase 1 (TAK1) blockade reverses the cardiac abnormalities in ubiquitin-specific protease 18-knockout (USP18-KO) mice after aortic banding (AB). A, Representative Western blots (left) and quantitative results (right) of the phosphorylated and total protein levels of TAK1, p38, and c-Jun N-terminal kinase 1/2 (JNK1/2) in hearts from USP18-KO mice after AB treated with dimethyl sulphoxide (DMSO) or 5Z-7-ox (n=4/group, *P<0.05 vs DMSO). B, Heart weight (HW)/body weight (BW), HW/tibia length, and lung weight (LW)/BW in wild-type (WT) and USP18-KO mice subjected to AB surgery treated with 5Z-7-ox or DMSO (n=8/group). C, Hematoxylin and eosin (H&E)-stained and picrosirius red-stained WT and USP18-KO hearts subjected to AB treated with 5Z-7-ox or DMSO (n=5-7 /group; scale bars are as indicated). D, Cross-sectional area of cardiomyocytes in WT and KO mice after AB surgery treated with 5Z-7-ox or DMSO (n=100 cells/group). E, Total collagen volume in WT and KO mice after AB on the addition of 5Z-7-ox or DMSO (n≥25 fields/ group). F, Echocardiographic parameters in WT and USP18-KO mice subjected to AB treated with 5Z-7-ox or DMSO (n=6-7/ group). *P<0.05 vs WT/DMSO; #P<0.05 vs KO/5Z-7-ox. The data are expressed as the mean±SD. EF indicates ejection fraction; LVEDd, LV end-diastolic dimension; and LVESd, LV end-systolic dimension. Top, TAK1 was precipitated from NRCMs lysates using anti-TAK1 antibody, followed by Western blot analysis performed with antibodies against USP18 or TAK1. Bottom, USP18 was precipitated from NRCMs lysates using anti-USP18 antibody, followed by Western blot analysis performed with antibodies against USP18 or TAK1. F, NRVMs transfected with AdshUSP18 or AdshRNA (left), or with AdGFP or AdUSP18 (right), followed by stimulation with PBS or Ang II for 24 h. Subsequently, cell lysates were subjected to immunoprecipitation (IP) with an anti-TAK1 antibody followed by Western blotting with an anti-Ub antibody.
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MAPKs are a well-studied family of proteins that play an integral role in cardiac signaling events, which are all activated in end-stage heart failure and contribute to the deterioration of cardiac remodeling. 29, 30 To examine the underlying mechanisms by which USP18 retards cardiac remodeling, we investigated the protein phosphorylation levels of ERK1/2, p38, and JNK1/2 under hypertrophic stimuli and revealed that only p38 and JNK1/2 were further enhanced by the loss of USP18 in response to AB. In addition, cardiac-specific USP18 overexpression almost completely blocked p38 and JNK1/2 activation in response to AB surgery or angiotensin II treatment. P38 and JNK1/2 are collectively called stress-activated MAPKs. 31 The overexpression of MKK6 (p38 activation) and MKK7 (JNK1/2 activation) exhibited the disease-causing effects of these kinases, inducing extreme cardiac dilation and contractile dysfunction. 32, 33 Inhibiting p38 and JNK1/2 signaling with an appropriate pharmacological agent could delay the transition toward heart failure. 20, 34 These results suggest that the heart-protective role of USP18 is likely attributed to its interference with p38 and JNK1/2 signaling.
We further investigated an upstream kinase of p38 and JNK1/2. TAK1 is a key kinase that activates downstream p38 and JNK1/2 kinase and plays a pivotal role during cardiac remodeling. [21] [22] [23] 35 Considering that TAK1 is an upstream regulator of p38 and JNK1/2 kinase, we predicted that USP18 may regulate TAK1 activity. Indeed, our results showed that USP18 deficiency enhanced TAK1 activity, whereas USP18 overexpression displayed the opposite response. TAK1-deficient mice fail to activate MAPKs. 36 In our study, the inhibition of TAK1 activity with a specific TAK1 inhibitor (5Z-7-ox), which has been widely used to demonstrate the specific involvement of TAK1 in diverse conditions, 37, 38 not only reduced the elevated levels of phosphorylated TAK1 and its downstream targets p38 and JNK1/2 but also abrogated the prohypertrophic effect of USP18 deficiency in response to pressure overload. Thus, we conclude that the mechanisms of the USP18-elicited antihypertrophic effects may plausibly be attributed to the inhibition of the TAK1-p38/JNK1/2 axis.
In this study, we found that USP18-mediated cardiac protection was attributed to the inhibition of the TAK1-p38/ JNK1/2 signaling axis, which was confirmed by utilizing a TAK1 inhibitor in USP18-KO mice and manifested a reversed effect during pathological remodeling. Modulation of signal transduction involves ubiquitination and deubiquitination. 8, 39 USP18 belongs to the USP family and was shown to have deubiquitinating enzyme activity early in 1999.
5 TAK1 is a ubiquitin-dependent kinase, and the polyubiquitination of TAK1 results in its autoactivation, which is also important for the activation of its downstream MAPK effectors in response to different stimuli. 23 Recently, a study by Liu et al 8 confirmed that USP18 binds to and inhibits the ubiquitination of the TAK1-TAB1 (TAK1-binding protein 1) complex, thereby suppressing TAK1 activation. This was consistent with our findings that USP18 physically interacted with and deubiquitinated TAK1, as well as decreased phosphorylation of TAK1 in hypertrophied hearts. Chen et al 40 discovered that the mutation of Lys562, a key Lys63-linked ubiquitination site of TAK1, leads to decreased TAK1 phosphorylation and the subsequent inhibition of MAPK signaling. Thus, USP18 may also restrain TAK1 activation via its deubiquitinating enzymatic activity in cardiac remodeling. Notably, inflammatory response also plays an indispensable pathological role in the pathogenesis of cardiac hypertrophy and heart failure. 41 Considering that USP18 is an important negative regulator of inflammation via interferon signaling in various organs (eg, pancreas and liver), 42 ,43 the regulatory effect of USP18 on inflammation may be another potential mechanism responsible for its protective role in this study, which warrants further study.
Together, our present work provides evidence of a previously unrecognized role for USP18 in protecting hearts against cardiac hypertrophy development in response to pressure overload. We reveal a novel interaction between USP18 and TAK1-p38/JNK1/2 signaling, providing new insights into the molecular basis of cardiac hypertrophy. Our data suggest that USP18 may hopefully delay the development of adverse remodeling after stable cardiac hypertrophy, considering its inhibitory effect against cardiac fibrosis and functional deterioration in current model. However, further study is still warranted to investigate whether USP18 can reverse stable cardiac hypertrophy.
Perspectives
This study provides in vivo and in vitro evidence that USP18 functions as a negative regulator of pathological cardiac remodeling by blocking the TAK1-p38/JNK1/2 signaling pathway. These findings uncover a novel USP18-TAK1-p38/ JNK1/2 signaling axis in the hypertrophic hearts, which sheds light on a potential target for the treatment of heart failure. November 2016
What Is New?
• The ubiquitin-specific protease 18 (USP18) protein level increases in failing human hearts and is upregulated both in vivo and in vitro in response to hypertrophic stimuli.
• USP18 exerts a protective role under remodeling, as evidenced by alleviated hypertrophy, relieved fibrosis, and blunted cardiac dysfunction.
• USP18 negatively regulates the transforming growth factor-β-activated kinase 1-p38/c-Jun N-terminal kinase 1/2 signaling pathway, and blocking transforming growth factor-β-activated kinase 1 offsets the beneficial effects of USP18 in cardiac remodeling.
What Is Relevant?
• Hypertrophic activators have been well investigated, but little is known about the negative modulators of cardiac hypertrophy.
• The role of USP18 in the heart is unexplored.
• This work advances our understanding of the important role of the unknown inhibitor that modulates cardiac remodeling by interacting with the well-defined signal transduction, thus providing a novel therapeutic target for heart failure.
Summary
This study clarifies that loss of USP18 exacerbates the hypertrophic response to aortic banding, whereas the overexpression of USP18 negatively regulates pressure overload-induced cardiac hypertrophy, fibrosis, and cardiac dysfunction. The USP18-transforming growth factor-β-activated kinase 1-p38/c-Jun N-terminal kinase 1/2 signaling axis is a key point for USP18 to participate in cardiac remodeling. These findings indicate that USP18 is a novel target for the treatment of heart failure. 
Novelty and Significance
